Real-life EValuation Of High Dose RosUvastatin in High Risk Patients After TitraTION

An Observational, Non-interventional, Multi-center Study to Evaluate Efficacy and Tolerability of High Dose Rosuvastatin in High Risk Patients After Titration

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00526721

Acronym

REVORUTION

Enrollment

1482

Registered

2007-09-10

Start date

2007-05-31

Completion date

2008-04-30

Last updated

2012-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholesterolemia

Keywords

Hypercholesterolemia, Crestor, LDL target goal, high risk patients, Naturalistic, Observational

Brief summary

To evaluate achievement ratio of treatment target goal in hypercholesterolemia patients with high risk after high dose rosuvastatin(20mg/day) titration

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* High-risk hyperlipidemia patients who are prescribed with rosuvastatin 10mg, based on the physician's clinical decision and fulfill the following criteria 1. Over 18 years of age 2. Have history of CHD or CHD risk equivalents, such as peripheral arterial disease, abdominal aortic aneurysm, symptomatic carotid artery disease (TIA or stroke of carotid origin or \>50% obstruction of carotid artery), DM, and 2+ risk factors with 10-year risk CHD\>20%

Exclusion criteria

1. Patients already taking other hyperlipidemic agents 2. Patients who do not fulfil the indication criteria for statin therapy 3. Patients who do not have baseline and/or follow-up lipid data to verify the efficacy data

Countries

South Korea

Outcome results